Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 12-Month High - What's Next?

Shares of Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $0.57 and last traded at $0.57, with a volume of 311 shares. The stock had previously closed at $0.56.

Sino Biopharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.15. The firm's 50 day simple moving average is $0.49 and its 200 day simple moving average is $0.44.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.